Skip to content

Influence of Peanut Consumption on Cardiovascular Risk Factors and the Gut Microbiome: A Randomized Clinical Trial

Influence of Peanut Consumption on Cardiovascular Risk Factors and the Gut Microbiome: A Randomized Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000050
Enrollment
Unknown
Registered
2024-04-24
Start date
2019-04-18
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular risk biomarkers and gut microbiome

Interventions

Arm A (Peanut Intervention):consume 50 gram plain peanuts (unsalted and unsweetened) daily for 16 weeks
Arm B (Control):No intervention. The controls follow their usual dietary habits for 16 weeks

Sponsors

Division of Epidemiology, Vanderebilt University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 100 participants (50 each arm) 1. Age: 40 – 70, FOBT negative 2. Do not consume peanut or other tree nuts/seeds more than 1 time per week. 3. Self-reported diabetes/prediabetes but not on diabetes medication 4. Or self-reported dyslipidemia but not on lipid or triglyceride lowing medication 5. Or BMI>=25 or waist circumference >90 cm for man or >80 cm for women 6. Or systolic/diastolic blood pressure = 130/85 mmHg

Exclusion criteria

Exclusion criteria: Individuals meet any of the following conditions are not eligible for the study 1. Known and suspected peanut/peanut containing products allergy 2. Kidney disease 3. Liver disease 4. Cardiovascular disease 5. Myocardial infarction 6. Cancer 7. Stroke 8. Drink more than 2 units of alcohol (2 cups of wine, 2 shuts of liquid or 2 cans of beer) weekly 9. On diabetes medications currently or during past 3 months 10. On lipid or triglyceride lowing medications currently or during past 3 months 11. Hospitalized in the past three months 12. Received chemotherapy, immune suppressive treatment, antibiotics during last 3 months 13. Have gained or lost more than 2.5 kg of weight in the last 3 months

Design outcomes

Primary

MeasureTime frame
Urinary metabolites;HbA1C;Gut microbiome profile;Plasma CRP;Lipid profile;Plasma insulin;Glucose;

Countries

Vietnam

Contacts

Public ContactXiao-Ou SHU

Vanderbilt Ingram Cancer Center, Department of Medicine, Division of Epidemiology, Vanderebilt University School of Medicine

xiao-ou.shu@vumc.org615-936-0713

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 5, 2026